Drugs / QLS31903
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05823285 | Mar 2023 → Jun 2025 overdue | cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS31903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05823285 ↗ |